Multiple Sclerosis and Hemophilia: This Biotech's Just Getting Started

Biogen's MS drug is off to a hot start, and its new hemophilia drugs are under FDA review.

Dave Williamson
Dave Williamson
May 19, 2013 at 2:00PM
Health Care

In this video, health-care analyst David Williamson discusses why Biogen Idec's party may just be getting started despite a huge run in the stock already. It has two hemophilia drugs under FDA review, but more importantly, its new groundbreaking multiple sclerosis drug is surpassing even the highest expectations of its launch.